Diabetes drug may have potential for Parkinson's
UK researchers have shared promising results of a phase 2 clinical trial of the type 2 diabetes drug exenatide in people with Parkinson's.
Study highlights the role of the immune system in Parkinson's
New research, reported in the scientific journal Nature, suggests that the immune system plays an important role in the progression of Parkinson's.
Low fat dairy products linked to Parkinson's
Higher consumption of low fat dairy products such as milk, butter, cheese and yoghurt is linked to a modest increase in risk of Parkinson’s, according to new research.
New method could lead to deep brain stimulation without surgery
Scientists have developed a new technique that shows promise as a non-invasive approach to deep brain stimulation.
Repurposing drugs to slow dementia
New research shows promise for repurposed drugs that slow dementia.
Reprogramming brain cells to reverse Parkinson’s
New research published in Nature Biotechnology shows that it may be possible to reprogramme cells inside the brain to reverse the symptoms of Parkinson's.
Hepatitis infection linked to Parkinson’s risk
Research suggests there may be a link between hepatitis infection and an increased risk of developing Parkinson's.
Welcome to our new Deputy Director of Research
We're excited to announce that Professor David Dexter has joined us as our new Deputy Director of Research.
Virtual company to create new Parkinson’s treatments
Parkinson's UK and the University of Sheffield have launched a new £1million virtual biotech company, Keapstone Therapeutics, to combine world-leading research from the University with funding and expertise from the charity to develop new treatments.
Phase II clinical trial of cancer drug announced
US researchers have announced the launch of a Phase II clinical trial of the cancer drug nilotinib in people with Parkinson’s.